GLP-1 agonists effective in Rxing MASH - metabolic dysfunction-assoc steatohepatitis (AKA NAFLD, NASH). DBRPCT w/ 1100 pts (mean BMI 34-35). A good perspective article from Sensible Medicine. https://t.co/NeaX5qcnPA https://t.co/loRPcwv8B9 https://t.co/ul8ko9cU4K
Links:
Perhaps the Strongest Benefit of GLP1a drugs is...
https://buff.ly/ikxmwJw
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatiti…
https://nej.md/3EVFAFM
May-06-2025
